Alnylam Pharmaceuticals (NASDAQ:ALNY) was upgraded by equities researchers at Goldman Sachs Group from a “buy” rating to a “conviction-buy” rating in a research report issued to clients and investors on Friday.

Other equities analysts also recently issued research reports about the company. Jefferies Group set a $102.00 price objective on Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, August 25th. B. Riley reduced their price objective on Alnylam Pharmaceuticals to $220.00 and set a “buy” rating on the stock in a research report on Wednesday, November 8th. BMO Capital Markets reiterated an “outperform” rating and set a $99.00 price objective (down previously from $105.00) on shares of Alnylam Pharmaceuticals in a research report on Wednesday, September 6th. Leerink Swann reiterated a “market perform” rating and set a $72.00 price objective (down previously from $83.00) on shares of Alnylam Pharmaceuticals in a research report on Friday, September 8th. They noted that the move was a valuation call. Finally, Needham & Company LLC lifted their price objective on Alnylam Pharmaceuticals from $85.00 to $125.00 and gave the stock a “buy” rating in a research report on Wednesday, September 20th. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $121.85.

Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at $125.59 on Friday. The company has a current ratio of 9.83, a quick ratio of 9.83 and a debt-to-equity ratio of 0.14. Alnylam Pharmaceuticals has a 12 month low of $35.98 and a 12 month high of $147.63.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.23) by ($0.11). The firm had revenue of $17.10 million during the quarter, compared to analyst estimates of $28.15 million. Alnylam Pharmaceuticals had a negative return on equity of 46.94% and a negative net margin of 664.70%. The business’s revenue was up 24.8% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.21) earnings per share. equities analysts anticipate that Alnylam Pharmaceuticals will post -5.21 EPS for the current year.

In other Alnylam Pharmaceuticals news, SVP Laurie Keating sold 30,000 shares of Alnylam Pharmaceuticals stock in a transaction on Friday, December 1st. The stock was sold at an average price of $135.89, for a total value of $4,076,700.00. Following the sale, the senior vice president now owns 41,500 shares in the company, valued at $5,639,435. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO John Maraganore sold 73,415 shares of Alnylam Pharmaceuticals stock in a transaction on Wednesday, November 22nd. The shares were sold at an average price of $130.90, for a total value of $9,610,023.50. Following the completion of the sale, the chief executive officer now owns 223,125 shares in the company, valued at approximately $29,207,062.50. The disclosure for this sale can be found here. Insiders sold 393,212 shares of company stock worth $48,109,436 in the last 90 days. Company insiders own 4.30% of the company’s stock.

Large investors have recently bought and sold shares of the business. Fayerweather Charles purchased a new stake in Alnylam Pharmaceuticals in the third quarter valued at $230,000. Watch Point Trust Co purchased a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at $235,000. Segall Bryant & Hamill LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at $235,000. Security National Bank of SO Dak purchased a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at $247,000. Finally, Boston Private Wealth LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at $247,000. Institutional investors own 88.43% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Alnylam Pharmaceuticals (ALNY) Rating Increased to Conviction-Buy at Goldman Sachs Group” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright & trademark law. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/12/17/alnylam-pharmaceuticals-alny-rating-increased-to-conviction-buy-at-goldman-sachs-group.html.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Stock Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related stocks with our FREE daily email newsletter.